Syros Pharmaceuticals Stock Investor Sentiment
| SYRS Stock | USD 0.27 0.02 8.00% |
Slightly above 56% of all Syros Pharmaceuticals' private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Syros Pharmaceuticals suggests that some traders are interested. Syros Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Syros Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Syros |
Syros Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Syros Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Syros Pharmaceuticals that are available to investors today. That information is available publicly through Syros media outlets and privately through word of mouth or via Syros internal channels. However, regardless of the origin, that massive amount of Syros data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Syros Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Syros Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Syros Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Syros Pharmaceuticals alpha.
Syros Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Jason Haas of 45344 shares of Syros Pharmaceuticals at 1.6762 subject to Rule 16b-3 | 09/12/2024 |
2 | The Schall Law Firm Encourages Shareholders With Losses In Syros Pharmaceuticals, Inc. To Join An Inquiry For Securities Law Violations | 09/24/2024 |
3 | Disposition of 6301 shares by Roth David of Syros Pharmaceuticals at 2.22 subject to Rule 16b-3 | 10/18/2024 |
4 | Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Encouraged To Contact The Schall Law Firm | 10/21/2024 |
5 | Acquisition by Fanucci Marsha of 4000 shares of Syros Pharmaceuticals subject to Rule 16b-3 | 11/07/2024 |
6 | Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression | 11/12/2024 |
7 | TD Cowen downgrades Syros Pharma stock to Hold on trial failure | 11/13/2024 |
8 | Avidity Partners Management LPs Strategic Acquisition in Syros Pharmaceuticals Inc | 11/15/2024 |
9 | Syros Pharmaceuticals announces major company changes | 11/18/2024 |
10 | Disposition of 46657 shares by Quirk Gerald E of Syros Pharmaceuticals at 0.2212 subject to Rule 16b-3 | 11/19/2024 |
11 | Syros Pharmaceuticals CEO Chee Conley sells shares worth 26,932 | 11/20/2024 |
12 | Kia Syros Compact SUV To Get Panoramic Sunroof- Teaser Confirms | 11/26/2024 |
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.